ASCO 2018 | Melanoma advancements: immunotherapy in the adjuvant setting

Paolo Ascierto

Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the adjuvant setting. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses how we now have the ability to use immunotherapy and targeted therapy in this setting, highlighting the CheckMate 238 study (NCT02388906), before pointing towards the questions still surrounding this area. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter